LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
Yuan FangGuochao LiaoBin YuPublished in: Journal of hematology & oncology (2019)
Histone demethylase LSD1 plays key roles during carcinogenesis, targeting LSD1 is becoming an emerging option for the treatment of cancers. Numerous LSD1 inhibitors have been reported to date, some of them such as TCP, ORY-1001, GSK-2879552, IMG-7289, INCB059872, CC-90011, and ORY-2001 currently undergo clinical assessment for cancer therapy, particularly for small lung cancer cells (SCLC) and acute myeloid leukemia (AML). This review is to provide a comprehensive overview of LSD1 inhibitors in clinical trials including molecular mechanistic studies, clinical efficacy, adverse drug reactions, and PD/PK studies and offer prospects in this field.
Keyphrases
- clinical trial
- acute myeloid leukemia
- cancer therapy
- adverse drug
- drug delivery
- dna methylation
- current status
- allogeneic hematopoietic stem cell transplantation
- emergency department
- phase ii
- signaling pathway
- randomized controlled trial
- acute lymphoblastic leukemia
- gene expression
- electronic health record
- pi k akt
- young adults
- cell proliferation
- replacement therapy
- drug induced
- childhood cancer